{
    "nct_id": "NCT04994535",
    "official_title": "A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of BOTOXÂ® (Botulinum Toxin Type A) Purified Neurotoxin Complex for the Treatment of Platysma Prominence",
    "inclusion_criteria": "* Participants must voluntarily sign and date an informed consent, approved by an independent ethics committee (IEC)/institutional review board (IRB), prior to the initiation of any screening or study specific procedures\n* Are willing and able to comply with procedures required in the protocol\n* Adult male or female, at least 18 years old at the time of signing the informed consent\n* Good health as determined by medical history, physical examination, vital signs, and investigator's judgment\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Any medical condition that may put the participant at increased medical risk with exposure to BOTOX, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, or any other condition that might interfere with neuromuscular function\n* Participant has an anticipated need for treatment with botulinum toxin of any serotype for any indication during the study (other than study intervention)\n* Anticipated need for surgery or overnight hospitalization during the study\n* Females who are pregnant or breastfeeding and are considering becoming pregnant or donating eggs during the study\n* Known immunization or hypersensitivity to any botulinum toxin serotype\n* History of clinically significant (per investigator's judgment) drug or alcohol abuse within the last 6 months\n* Lower facial and neck hair, scarring (e.g., acne), or other abnormal variations that may interfere with photography (such that photograph is not acceptable)\n* Tattoos, jewelry, or clothing that cannot be removed, and that obscure the target area of interest",
    "miscellaneous_criteria": ""
}